Real-life experience with sorafenib for advanced and refractory desmoid-type fibromatosis.

Delphine SchampersAlexander Decruyenaere Jacobs Celine Lore D F Lapeire

Published in: Acta oncologica (Stockholm, Sweden) (2024)

Real-life data on the use of sorafenib in the treatment of DF is consistent with published data in clinical trial setting. Sorafenib is an effective treatment option for progressive DF although associated with significant toxicity and the need for rapid dose reduction.

Keyphrases

clinical trial
multiple sclerosis
big data
systematic review
study protocol
data analysis
phase ii
replacement therapy